A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias

Abstract

Ponatinib had significant antileukemic activity across categories of disease stage and mutation status. (Funded by Ariad Pharmaceuticals and others; PACE ClinicalTrials.gov number, NCT01207440 .).